Let’s support Gabriel and Olivier

Gabriel Paquet Desbiens and Olivier Houde launched a huge challenge to raise funds for the Foundation to pursue its mission. These two childhood friends will cycle or run from Baie St-Paul to Ville de la Baie in three days starting September 15. Gabriel is affected by...

Interested in joining the ARSACS research team ?

The Foundation is inviting you to send your research proposal. The research grant could be as high as $100,000 for a 12-month period and with possibility for renewal. The Scientific Advisory Board of the Foundation will evaluate each application. Call for Proposal,...

$1.1M raised for ARSACS Research – Thank you !

On behalf of the persons living with ARSACS, their families and the Foundation, thank you to all of you for your generosity : Mr. Vincent Chiara, Honorary president, sponsors, partners, donors and volunteers. With your support, the Foundation can pursue its mission to...

The Krogan Lab team continues working on ARSACS

The Krogan Lab researchers are currently performing mechanistic follow-up studies on a subset of the protein-protein interactions they  identified. “Our affinity purification mass spectrometry studies on sacsin have revealed a protein-proteininteraction with DAPK...

Drs Wolter & Chapple’s ARSACS research published

Drs Justin Wolter and Paul Chapple’ s ARSACS research “Multi-omic profiling reveals the ataxia protein sacsinis required for integrin trafficking and synaptic organization” has been published in the Cell Reports on November 1, 2022. Furthermore, the...

$940,000 for ARSACS research in 2022-2023!

As part of its mission, the Foundation is financing 15 teams of researchers in Quebec/Canada and internationally for a total amount of $940,000 for 2022-2023. 10 promissing projects whose objective is to discover a treatment for ARSACS. Project description.

“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS):  A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood” – Drs. Justin Wolter, Matthis Synofzik & David Mengel

  It is well established in neurodegenerative diseases that early therapeutic intervention – ideally before neurodegenerative cascades begin to breakdown neuronal function – is key to the success of disease-modifying therapies. Yet we do not understand the...